ARID1A and female reproductive organ cancer: To test if combination BRD4i with either ATRi or WEE1i, were more effective compared to monotherapy and if combination therapy efficacy was dependent on ARID1A mutation status, we evaluated BRD4i combinations using a large panel of ARID1AMUT or ARID1AWT gynecologic cancer lines (CCOC lines: OVTOKO, TOV21G, OVISE, JHOC-9, OVMANA, ES-2, JHOC-5, OV207, and OVCA429; HGSOC lines: WO-24, OVKATE, and OVCAR-8; Fig. 1).